MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model

Vaccine

Volumn 34, Issue 24, 2016, Pages 2648-2655

  Zhang, Haihong ^a   Liu, Chenlu ^a   Zhang, Fangfang ^a   Geng, Fei ^a   Xia, Qiu ^a   Lu, Zhenzhen ^a   Xu, Ping ^a   Xie, Yu ^a   Wu, Hui ^a   Yu, Bin ^a   Wu, Jiaxin ^a   Yu, Xianghui ^a   Kong, Wei ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Cancer vaccine; DNA prime rAd boost; IL 2 adjuvant; MUC1; Survivin

Indexed keywords

ADENOVIRUS VACCINE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MUCIN 1; SURVIVIN; TUMOR VACCINE; BIRC5 PROTEIN, HUMAN; CANCER VACCINE; HYBRID PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MUC1 PROTEIN, HUMAN; TUMOR ANTIGEN; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; ADENOVIRIDAE; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; FEMALE; GENE VECTOR; HEK293 CELL LINE; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; T LYMPHOCYTE;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL PROLIFERATION; FEMALE; GENETIC VECTORS; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MUCIN-1; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VACCINES, COMBINED; VACCINES, DNA;

EID: 84964575601     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.04.045     Document Type: Article

References (33)

1. Huber C.H., Wolfel T. Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 2004, 130(July (7)):367-374.
2. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8(January (1)):61-70.
3. Bernatchez C., Zhu K., Li Y., Andersson H., Ionnides C., Fernandez-Vina M., et al. Altered decamer and nonamer from an HLA-A0201-restricted epitope of survivin differentially stimulate T-cell responses in different individuals. Vaccine 2011, 29(April (16)):3021-3030.
4. Wang Y.Q., Zhang H.H., Liu C.L., Xia Q., Wu H., Yu X.H., et al. Correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats in colorectal cancer. Asian Pac J Cancer Prev 2012, 13(11):5557-5562.
5. Lennerz V., Gross S., Gallerani E., Sessa C., Mach N., Boehm S., et al. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 2014, 63(April (4)):381-394.
6. Zhang H., Wang Y., Liu C., Zhang L., Xia Q., Zhang Y., et al. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother 2012, 61(October (10)):1857-1867.
7. Wang Y.Q., Zhang H.H., Liu C.L., Wu H., Wang P., Xia Q., et al. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. Int Immunopharmacol 2013, 17(September (1)):9-17.
8. Nath S., Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 2014, 20(June (6)):332-342.
9. Tang C.K., Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines 2008, 7(September (7)):951-962.
10. Kufe D.W. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009, 9(December (12)):874-885.
11. Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15(September (17)):5323-5337.
12. Brockhausen I., Yang J.M., Burchell J., Whitehouse C., Taylor-Papadimitriou J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 1995, 233(October (2)):607-617.
13. Nath S., Daneshvar K., Roy L.D., Grover P., Kidiyoor A., Mosley L., et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis 2013, 2:e51.
14. Gendler S.J., Spicer A.P. Epithelial mucin genes. Annu Rev Physiol 1995, 57:607-634.
15. Palmer M., Parker J., Modi S., Butts C., Smylie M., Meikle A., et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001, 3(August (1)):49-57. discussion 58.
16. Domenech N., Henderson R.A., Finn O.J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995, 155(November (10)):4766-4774.
17. Tang C.K., Katsara M., Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 2008, 7(September (7)):963-975.
18. Zhang S., Zhang H., Shi H., Yu X., Kong W., Li W. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats. Hum Immunol 2008, 69(April-May (4-5)):250-258.
19. Wang Y., Liu C., Xia Q., Wang P., Li B., Lu Z., et al. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Oncol Rep 2014, 31(March (3)):1437-1444.
20. Noguchi M., Kakuma T., Uemura H., Nasu Y., Kumon H., Hirao Y., et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010, 59(July (7)):1001-1009.
21. Iinuma H., Fukushima R., Inaba T., Tamura J., Inoue T., Ogawa E., et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med 2014, 12:84.
22. Disis M.L., Gad E., Herendeen D.R., Lai V.P., Park K.H., Cecil D.L., et al. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res 2013, 6(December (12)):1273-1282.
23. Zhang H., Wang Y., Liu C., Zhang L., Xia Q., Zhang Y., et al. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother 2012, 61(October (10)):1857-1867.
24. Zhang L., Du J., Wang Y., Liu C., Xia Q., Zhang X., et al. Establishment of a tumor-bearing mouse model stably expressing human tumor antigens survivin and MUC1 VNTRs. Chem Res Chin Univ 2012, 28(2):259-263.
25. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(November (7528)):568-571.
26. Loeffler M., Kruger J.A., Niethammer A.G., Reisfeld R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Investig 2006, 116(July (7)):1955-1962.
27. Chen J., Guo X.Z., Li H.Y., Liu X., Ren L.N., Wang D., et al. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA. Vaccine 2013, 31(September (41)):4585-4590.
28. Hayton E.J., Rose A., Ibrahimsa U., Del Sorbo M., Capone S., Crook A., et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLOS ONE 2014, 9(7):e101591.
29. Pol J., Bloy N., Obrist F., Eggermont A., Galon J., Herve Fridman W., et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2014, 3(January (1)):e28185.
30. Appaiahgari M.B., Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther 2015, 15(March (3)):337-351.
31. Khare R., Chen C.Y., Weaver E.A., Barry M.A. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011, 11(August (4)):241-258.
32. Ragonnaud E., Holst P. The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Ther Adv Vaccines 2013, 1(May (1)):33-47.
33. Kamphorst A.O., Araki K., Ahmed R. Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. Vaccine 2015, 33(June (Suppl. 2)):B21-B28.